Literature DB >> 32142964

Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop.

Robert Naclerio1, Fuad Baroody2, Claus Bachert3, Benjamin Bleier4, Larry Borish5, Erica Brittain6, Geoffrey Chupp7, Anat Fisher8, Wytske Fokkens9, Philippe Gevaert3, David Kennedy10, Jean Kim1, Tanya M Laidlaw11, Jake J Lee12, Jay F Piccirillo12, Jayant M Pinto2, Lauren T Roland13, Robert P Schleimer14, Rodney J Schlosser15, Julie M Schwaninger6, Timothy L Smith16, Bruce K Tan14, Ming Tan17, Elina Toskala18, Sally Wenzel19, Alkis Togias20.   

Abstract

The development of biologics targeting various aspects of type 2 inflammation for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) will provide clinicians with powerful tools to help treat these patients. However, other therapies are also available, and positioning of biologics in a management algorithm will require comparative trials. In November 2019, the National Institute of Allergy and Infectious Diseases convened a workshop to consider potential future trial designs. Workshop participants represented a wide spectrum of clinical specialties, including otolaryngology, allergy, and pulmonary medicine, as well as expertise in CRSwNP pathophysiology and in trial methodology and statistics. The workshop discussed the current state of knowledge in CRSwNP and considered the advantages and disadvantages of various clinical trial or observational study designs and various clinical outcomes. The output from this workshop, which is presented in this report, will hopefully provide investigators with adequate information and ideas to design future studies and answer critical clinical questions. It will also help clinicians understand the current state of the management of CRSwNP and its gaps and be more able to interpret the new information to come.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical trials; Dupilumab; Mepolizumab; Nasal polyposis; Omalizumab; Outcomes; Rhinosinusitis; Type 2 inflammation

Mesh:

Substances:

Year:  2020        PMID: 32142964      PMCID: PMC8177483          DOI: 10.1016/j.jaip.2020.02.023

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  161 in total

1.  Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease.

Authors:  J Morgan Knight; Pijus Mandal; Pietro Morlacchi; Garbo Mak; Evan Li; Matthew Madison; Cameron Landers; Brandon Saxton; Ed Felix; Brian Gilbert; Joel Sederstrom; Atul Varadhachary; Melissa M Singh; Dev Chatterjee; David B Corry; John S McMurray
Journal:  J Biol Chem       Date:  2018-05-08       Impact factor: 5.157

2.  Correlation of tissue eosinophil count and chemosensory functions in patients with chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery.

Authors:  Lichuan Zhang; Chunhua Hu; Zhifu Sun; Pengfei Han; Xingyu Han; Haili Sun; Dawei Wu; Qianwen Lv; Xiaoguang Yan; Wei Yu; Thomas Hummel; Yongxiang Wei
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-01       Impact factor: 2.503

3.  Functional endoscopic sinus surgery: evaluation, surgery, and follow-up of 250 patients.

Authors:  H L Levine
Journal:  Laryngoscope       Date:  1990-01       Impact factor: 3.325

4.  Long-term revision rates for endoscopic sinus surgery.

Authors:  Kristine A Smith; Richard R Orlandi; Gretchen Oakley; Huong Meeks; Karen Curtin; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2018-12-20       Impact factor: 3.858

5.  Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus.

Authors:  Tetsuji Takabayashi; Yoshimasa Imoto; Masafumi Sakashita; Yukinori Kato; Takahiro Tokunaga; Kanako Yoshida; Norihiko Narita; Tamotsu Ishizuka; Shigeharu Fujieda
Journal:  Allergol Int       Date:  2017-04-04       Impact factor: 5.836

6.  Effects of endoscopic sinus surgery on objective and subjective measures of cognitive dysfunction in chronic rhinosinusitis.

Authors:  Frederick Yoo; Rodney J Schlosser; Kristina A Storck; Kimia G Ganjaei; Nicholas R Rowan; Zachary M Soler
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-26       Impact factor: 3.858

7.  Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study.

Authors:  D Hastan; W J Fokkens; C Bachert; R B Newson; J Bislimovska; A Bockelbrink; P J Bousquet; G Brozek; A Bruno; S E Dahlén; B Forsberg; M Gunnbjörnsdóttir; L Kasper; U Krämer; M L Kowalski; B Lange; B Lundbäck; E Salagean; A Todo-Bom; P Tomassen; E Toskala; C M van Drunen; J Bousquet; T Zuberbier; D Jarvis; P Burney
Journal:  Allergy       Date:  2011-05-24       Impact factor: 13.146

8.  Quantification for staging sinusitis. The Staging and Therapy Group.

Authors:  V J Lund; D W Kennedy
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1995-10

9.  Allergic inflammatory memory in human respiratory epithelial progenitor cells.

Authors:  Jose Ordovas-Montanes; Daniel F Dwyer; Sarah K Nyquist; Kathleen M Buchheit; Marko Vukovic; Chaarushena Deb; Marc H Wadsworth; Travis K Hughes; Samuel W Kazer; Eri Yoshimoto; Katherine N Cahill; Neil Bhattacharyya; Howard R Katz; Bonnie Berger; Tanya M Laidlaw; Joshua A Boyce; Nora A Barrett; Alex K Shalek
Journal:  Nature       Date:  2018-08-22       Impact factor: 49.962

10.  Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps.

Authors:  Neil Bhattacharyya; Sara Villeneuve; Vijay N Joish; Caroline Amand; Leda Mannent; Nikhil Amin; Paul Rowe; Jaman Maroni; Laurent Eckert; Tony Yang; Asif Khan
Journal:  Laryngoscope       Date:  2019-02-05       Impact factor: 3.325

View more
  8 in total

1.  Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps.

Authors:  Asif H Khan; Matthew Reaney; Isabelle Guillemin; Lauren Nelson; Shanshan Qin; Siddhesh Kamat; Leda Mannent; Nikhil Amin; Diane Whalley; Claire Hopkins
Journal:  Laryngoscope       Date:  2021-08-26       Impact factor: 2.970

2.  Endotyping chronic rhinosinusitis based on olfactory cleft mucus biomarkers.

Authors:  Zachary M Soler; Rodney J Schlosser; Todd E Bodner; Jeremiah A Alt; Vijay R Ramakrishnan; Jose L Mattos; Jennifer K Mulligan; Jess C Mace; Timothy L Smith
Journal:  J Allergy Clin Immunol       Date:  2021-02-04       Impact factor: 10.793

Review 3.  Targetable pathogenic mechanisms in nasal polyposis.

Authors:  Alexander L Schneider; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2021-03-03       Impact factor: 5.426

4.  Latest advances in chronic rhinosinusitis with nasal polyps endotyping and biomarkers, and their significance for daily practice.

Authors:  Alma Aurelia Maniu; Maria Ida Perde-Schrepler; Corina Bianca Tatomir; Mihai Ionuţ Tănase; Maximilian George Dindelegan; Vlad Andrei Budu; Gheorghe Doinel Rădeanu; Marcel Cosgarea; Carmen Aurelia Mogoantă
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

5.  The Treatment Paradigm of Chronic Rhinosinusitis with Nasal Polyps in the COVD-19 Era.

Authors:  Lauren T Roland; Jayant M Pinto; Robert M Naclerio
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-24

6.  Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.

Authors:  Stella E Lee; Claire Hopkins; Joaquim Mullol; Jérôme Msihid; Isabelle Guillemin; Nikhil Amin; Leda P Mannent; Yongtao Li; Shahid Siddiqui; Chien-Chia Chuang; Siddhesh Kamat; Asif H Khan
Journal:  Allergy       Date:  2022-02-01       Impact factor: 14.710

7.  Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.

Authors:  Nicola Lombardo; Corrado Pelaia; Marco Ciriolo; Marcello Della Corte; Giovanna Piazzetta; Nadia Lobello; Pasquale Viola; Girolamo Pelaia
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

8.  A modest proposal for a new way forward for clinical research: Involve insurance companies.

Authors:  James H Clark; Jayant M Pinto; Robert M Naclerio
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-09       Impact factor: 5.426

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.